A detailed history of Barclays PLC transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Barclays PLC holds 361,093 shares of OCUL stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
361,093
Previous 110,106 227.95%
Holding current value
$2.47 Million
Previous $491,000 569.25%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.85 - $10.93 $966,299 - $2.74 Million
250,987 Added 227.95%
361,093 $3.29 Million
Q4 2023

Feb 15, 2024

BUY
$2.08 - $4.52 $175,017 - $380,326
84,143 Added 324.09%
110,106 $491,000
Q3 2023

Nov 07, 2023

BUY
$3.14 - $5.04 $15,197 - $24,393
4,840 Added 22.91%
25,963 $81,000
Q2 2023

Aug 03, 2023

SELL
$4.6 - $7.64 $1.19 Million - $1.98 Million
-258,564 Reduced 92.45%
21,123 $109,000
Q1 2023

May 04, 2023

SELL
$2.79 - $6.27 $109,220 - $245,451
-39,147 Reduced 12.28%
279,687 $1.47 Million
Q4 2022

Feb 13, 2023

BUY
$2.61 - $4.41 $823,629 - $1.39 Million
315,567 Added 9659.23%
318,834 $896,000
Q3 2022

Nov 03, 2022

SELL
$4.09 - $6.5 $53,587 - $85,163
-13,102 Reduced 80.04%
3,267 $14,000
Q2 2022

Aug 12, 2022

SELL
$3.01 - $5.22 $48,497 - $84,104
-16,112 Reduced 49.6%
16,369 $66,000
Q1 2022

May 16, 2022

SELL
$4.83 - $7.35 $448,373 - $682,307
-92,831 Reduced 74.08%
32,481 $161,000
Q4 2021

Feb 14, 2022

BUY
$6.16 - $12.07 $305,382 - $598,370
49,575 Added 65.46%
125,312 $873,000
Q3 2021

Nov 09, 2021

BUY
$9.7 - $14.34 $575,879 - $851,351
59,369 Added 362.71%
75,737 $757,000
Q2 2021

Aug 13, 2021

SELL
$13.43 - $19.16 $661,602 - $943,879
-49,263 Reduced 75.06%
16,368 $231,000
Q1 2021

May 13, 2021

BUY
$15.82 - $22.11 $683,471 - $955,218
43,203 Added 192.63%
65,631 $1.08 Million
Q4 2020

Feb 11, 2021

SELL
$7.91 - $22.95 $63,430 - $184,036
-8,019 Reduced 26.34%
22,428 $464,000
Q3 2020

Nov 12, 2020

BUY
$7.36 - $9.87 $6,447 - $8,646
876 Added 2.96%
30,447 $231,000
Q2 2020

Aug 12, 2020

BUY
$4.67 - $8.95 $72,581 - $139,100
15,542 Added 110.78%
29,571 $246,000
Q1 2020

May 13, 2020

SELL
$3.95 - $7.4 $112,322 - $210,426
-28,436 Reduced 66.96%
14,029 $70,000
Q4 2019

Feb 10, 2020

SELL
$2.57 - $4.73 $35,291 - $64,952
-13,732 Reduced 24.44%
42,465 $168,000
Q3 2019

Nov 14, 2019

SELL
$3.04 - $5.32 $29,080 - $50,891
-9,566 Reduced 14.55%
56,197 $171,000
Q2 2019

Aug 14, 2019

BUY
$2.46 - $4.52 $105,497 - $193,840
42,885 Added 187.45%
65,763 $290,000
Q1 2019

May 15, 2019

BUY
$3.51 - $4.77 $2,277 - $3,095
649 Added 2.92%
22,878 $91,000
Q4 2018

Feb 14, 2019

SELL
$3.87 - $7.11 $97,202 - $178,581
-25,117 Reduced 53.05%
22,229 $88,000
Q3 2018

Nov 14, 2018

BUY
$5.42 - $6.99 $126,036 - $162,545
23,254 Added 96.52%
47,346 $325,000
Q2 2018

Aug 14, 2018

SELL
$5.99 - $8.17 $24,978 - $34,068
-4,170 Reduced 14.75%
24,092 $162,000
Q1 2018

May 15, 2018

BUY
$4.66 - $7.08 $112,529 - $170,967
24,148 Added 586.97%
28,262 $184,000
Q4 2017

Feb 14, 2018

SELL
$3.73 - $6.37 $16,434 - $28,066
-4,406 Reduced 51.71%
4,114 $18,000
Q3 2017

Nov 14, 2017

BUY
$5.28 - $6.88 $44,985 - $58,617
8,520
8,520 $52,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $526M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.